MAY 2018

NeuClone Announces Preclinical Results for Stelara® (ustekinumab) Biosimilar Candidate

Full Press Release here.

JAN 2018

NeuClone discloses details of its fifth product: a biosimilar candidate for Prolia®/XGEVA®

Full Press Release here.

NOV 2017

NeuClone attends the 23rd International Partnering Conference BIO-Europe

NeuClone attends latest BIO meeting in Berlin.

MAY 2017

NeuClone presents at the 25th ESACT Meeting

NeuClone presents new data on its NeuMAX platform enabling the cost effective manufacture of biosimilars

JAN 2017

NeuClone attends 35th Annual J.P. Morgan Healthcare Conference

NeuClone was invited to attend the J.P. Morgan conference and engaged in business development activities

NOV 2016

NeuClone presents at the 22nd Annual BIO-Europe Conference

Dr. Noelle Sunstrom, CEO of NeuClone, presented a company profile at BIO-Europe 2016

AUG 2016

US patent granted for NeuCHO®

NeuClone has been granted a US patent for its proprietary host cell line NeuCHO®. NeuCHO® is derived from the Chinese Hamster Ovary (CHO) cell line having enhanced growth and viability due to the expression of an autocrine growth factor.

The patent was first granted from IP Australia in February 2016 after its publication in January 2016.

JUN 2016

Dr. Angelo Perani presents at the 12th annual Cell Line Development and Engineering conference. His presentation explores the selection of high productivity and high target bioactivity cell lines for the production of biosimilars.

Dr. Russell Howard, John Oksinski and Dr. Noelle Sunstrom attend the BIO International Convention participating in over 30 “BIO One-on-One Partnering™” meetings in 3 days.

MAY 2016

Dr. Noelle Sunstrom attends Cell Culture Engineering XV.

OCT 2015

The Hon Sussan Ley MP, Minister of Health, officially opens NeuClone’s new biomanufacturing facilities.

The new facility includes three new laboratories two of which have been used for GMP manufacture in the past. The 315 square meters of new space is located opposite NeuClone’s current facilities and will house a new high throughput sterile liquid handling system, an ambr 15 microbioreactor, Solentim cell imagers as well as a state-of-the art FACS facility.

FEB 2015

Dr. Angelo Perani joins NeuClone’s scientific team as Chief Scientific Officer

Dr Angelo Perani has over 15 years experience in Mammalian Cell Culture working for the Ludwig Institute for Cancer Research and Lonza Biologics. He holds a European PhD from the INPL-France on Apoptosis in Mammalian Cell Culture and its applications to the production of monoclonal antibodies from a joint project between the INSERM U284 in France, the European Cell Bank (ECACC) in the UK and the University of Barcelona in Spain. This was followed by a post-doc fellowship at the Animal Cell Technology Group (University of Birmingham UK) investigating the impact of over-expressing bcl-2 in industrial cell lines. He was also responsible of an EU-funded project “Suppression of Apoptosis in Large Scale Biological Production Systems” in collaboration with Hamburg-Harburg University in Germany.

JAN 2015

Dr. Russell Howard attends JP Morgan Healthcare Conference.

JUN 2014

NeuClone, a Sydney biotechnology company, announces a worldwide partnership with Serum Institute of India Ltd to produce a portfolio of biosimilar drugs

NeuClone Pty Ltd (NeuClone) in Sydney, Australia and The Serum Institute of India Ltd (Serum Institute) based in Pune, India have today announced a licensing agreement and joint development partnership to manufacture and supply 10 biosimilar monoclonal antibody drugs globally for treatment of diseases such as cancer and autoimmune disorders.  Each of these antibody drugs address markets between $100’s of millions and $10B.

The partnership leverages NeuClone’s patented technology to generate protein drugs at much reduced cost from proprietary manufacturing cell lines and the immense biologics manufacturing capability of Serum Institute, the world’s largest vaccine producer. “After several years of technology development and building our team expertise, NeuClone is very pleased to launch this multi-product co-development program with Serum Institute. Our products will exemplify the competitive advantages of our NeuMAXTM technology platform for cell line development”, said Noelle Sunstrom, NeuClone’s Founder and CEO.

NeuClone retains license to the jointly developed biosimilars for the developed markets of USA, Europe, Canada, Australia, Taiwan, Japan and South Korea. For these markets NeuClone is seeking partnerships with large Pharmaceutical and Generics companies who can best deliver these products via their existing market channels.

For the rest of the world, including India, China, South East Asia, The Middle East, South America and Africa, Serum Institute has exclusive license for marketing and sales. In these markets, until now unable to afford these drugs, Serum Institute is well positioned to leverage its growing business as the world’s largest vaccine manufacturer by number of doses and as a global supplier of affordable vaccines. The company is ranked India’s No. 1 biotechnology company, manufacturing highly specialized life-saving biologic therapeutics since 1967.  Serum Institute has a proven track record over four decades for supply of vaccines at an extremely affordable cost. We plan to extend the vision set by Dr. C.S. Poonawalla to develop biosimilar monoclonal antibodies at an extremely affordable cost through this collaboration” said Mr. A.C. Poonawalla, CEO & Executive Director, Serum Institute of India.  Umesh Shaligram, Serum Institute’s Director of R&D added, “For this new strategic initiative in the biosimilar monoclonal antibodies market we are combining our extensive biologics manufacturing and distribution expertise and cost advantages with NeuClone’s technology for high quality and low cost of goods”.

The partnership will have multiple products in development simultaneously such that all 10 products will transition through clinical trials and enter the market.

MAY 2014

Dr Noelle Sunstrom addresses IBC conference Cell Line Development & Engineering Asia 2014

MAR 2014

Mr. John Macphillamy joins NeuClone as Chief Financial Officer, Legal Counsel and Executive Director

JAN 2014

David Anstice  joins NeuClone Board of Directors as Non-executive Director.

Dr Russel J. Howard  attends J.P. Morgan 32nd Annual Healthcare Conference.

MAY 2013

Dr Noelle Sunstrom, CEO, co-chairs Biomanufacturing Monoclonal Antibodies Session at the 4th Annual Biosimilars Asia 2013 conference

MAR 2013

Russel J Howard Takes out Overrall Winner of Advance Global Australia Awards 2013

Russell Howard was the overall Advance Global Australian Award winner, selected from the category winners and announced at the event. The Advance Global Australian Awards celebrate the achievements of Australians living overseas who exhibit remarkable talent, ambition and exceptional vision. They are the only awards to recognize the important contributions of the more than one million Australians living abroad esayscaptain writing. The Awards Forum and Ceremony took on 21 March 2013, at the Museum of Contemporary Art, Sydney, Australia.

JAN 2013

Dr Russell J Howard joins NeuClone as Executive Chairman

Contact Us

Not readable? Change text. captcha txt